Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility lociCatharine West, Fredrick R. Schumacher, Ali Amin Al Olama et al.|Nature Genetics|2018Cited by 1k
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL StudyTomasz M. Beer, Bertrand Tombal, Michael Borre et al.|European Urology|2016Cited by 414
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trialKarim Fizazi, Mika Mustonen, Christophe Massard et al.|The Lancet Oncology|2014Cited by 194
Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate CancerGillian Vandekerkhove, Alexander W. Wyatt, Werner J. Struss et al.|European Urology|2019Cited by 183
Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variantsTokhir Dadaev, Lorelei A. Mucci, Edward J. Saunders et al.|Nature Communications|2018Cited by 113